Application of aloe-emodin in preparation of drugs reducing blood lipid and liver lipid

An aloe-emodin and blood lipid-lowering technology, which is applied in the field of medicine to achieve the effects of strong lipid-lowering effect, high cost performance and strong medicinal properties

Active Publication Date: 2016-06-15
HARBIN MEDICAL UNIVERSITY
View PDF3 Cites 13 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there is no report on the effect of aloe-emodin on lowering blood fat and liver fat at home and abroad.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of aloe-emodin in preparation of drugs reducing blood lipid and liver lipid
  • Application of aloe-emodin in preparation of drugs reducing blood lipid and liver lipid
  • Application of aloe-emodin in preparation of drugs reducing blood lipid and liver lipid

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0028] Embodiment 1 aloe-emodin acute toxicity test

[0029] 1 Experimental method:

[0030] The acute toxicity of aloe-emodin was evaluated by the maximum tolerated dose method. The specific method is as follows: 40 mice were randomly divided into a control group and an experimental group, with 20 mice in each group, half male and half male. Aloe-emodin is prepared into a 0.5g / mL suspension with 1% (quality of Tween-80 / volume of water) Tween-80 aqueous solution, and the experimental group is based on (50g aloe-emodin) / (kg mouse body weight) The dose was given to the mice by intragastric administration, and the administration was divided into 3 times in 1 day, each time interval was 3h. The mice were administrated with 10 mL / kg of 0.5 g / mL aloe-emodin suspension for the first time. At the same time, mice in the control group were intragastrically administered 1% Tween-80 aqueous solution according to the same dosage regimen.

[0031] After administration, the mice were fed...

Embodiment 2

[0034] Example 2 Pharmacodynamic study of aloe-emodin hypolipidemic effect

[0035] 1 Experimental method:

[0036] 60 Wistar male rats were randomly divided into six groups: normal control group, high-fat model group, atorvastatin group (7.2mg atorvastatin / kg rat body weight, equivalent to the maximum clinical dose of human body), high-dose Aloe-emodin group (100mg aloe-emodin / kg rat body weight), medium-dose aloe-emodin group (50mg aloe-emodin / kg rat body weight) and low-dose aloe-emodin group (25mg aloe-emodin / kg rat body weight ), 10 in each group. The normal control group was fed with 20g / bird of common feed, and the rest of the groups were fed with 20g / high-fat feed for 4 weeks, with free drinking water, to establish a hyperlipidemia model.

[0037] Atorvastatin was formulated with 1% Tween-80 to prepare 0.72 mg / mL suspension, and aloe-emodin was prepared with 1% Tween-80 to prepare 10, 5 and 2.5 mg / mL suspensions, respectively. The atorvastatin group used atorvastati...

Embodiment 3

[0043] Example 3 Pharmacodynamic study of the effect of aloe-emodin on reducing liver fat

[0044] 1 Experimental method:

[0045] 60 Wistar male rats were randomly divided into six groups: normal control group, high-fat model group, atorvastatin group (7.2mg atorvastatin / kg rat body weight), high-dose aloe-emodin group (400mg aloe-rhubarb Aloe-emodin / kg rat body weight), middle dose aloe-emodin group (200mg aloe-emodin / kg rat body weight) and low-dose aloe-emodin group (100mg aloe-emodin / kg rat body weight), 10 rats in each group. The method for establishing the hyperlipidemia model is the same as in Example 2.

[0046] Atorvastatin was formulated with 1% Tween-80 to prepare 0.72 mg / mL suspension, and aloe-emodin was prepared with 1% Tween-80 to prepare 40, 20 and 10 mg / mL suspension respectively. In the atorvastatin group, atorvastatin suspension was administered to rats at a dose of 7.2 mg / kg, and in the high, middle, and low dose aloe-emodin groups, the doses of 400, 200...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Belonging to the field of medical technologies, the present invention discloses application of aloe-emodin in preparation of drugs reducing blood lipid and liver lipid. Specifically, blood lipid refers to total cholesterol and low density lipoprotein in serum, and liver lipid refers to total cholesterol in liver. Toxicity tests show that aloe-emodin has no obvious toxic and side effect. Pharmacodynamic tests of aloe-emodin show that aloe-emodin can significantly reduce the total cholesterol and low density lipoprotein in hyperlipidemia animal model serum, and has obvious blood lipid reducing effect. At the same time, aloe-emodin can also significantly reduce the total cholesterol content of a hyperlipidemia animal model liver, and has obvious liver lipid reducing effect. Therefore, the invention puts forward the application of aloe-emodin in reduction of blood lipid and liver lipid, aloe-emodin has the characteristics of significant lipid reducing effect, low toxicity, no irritation, low price, and convenient production, transportation, storage and taking, and can have broad application prospects as a blood lipid and liver lipid reducing drug.

Description

technical field [0001] The invention relates to a new application of aloe-emodin, in particular to the application of aloe-emodin in the preparation of drugs for lowering blood fat and liver fat, and belongs to the technical field of medicine. Background technique [0002] In recent years, with the improvement of people's living standards, the pressure of life and work has intensified, the intake of dietary factors such as high cholesterol and high saturated fatty acids has increased sharply, the amount of exercise has decreased significantly, and the incidence of hyperlipidemia has increased year by year. Hyperlipidemia is due to abnormal fat metabolism or operation, which makes the level of lipids such as cholesterol in plasma higher than normal. Studies have shown that hyperlipidemia can directly cause a series of diseases with high fatality rate, and it is an important risk factor for diseases such as hypertension, diabetes, coronary heart disease, myocardial infarction,...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/122A61P3/06A61P1/16
CPCA61K31/122
Inventor 杜智敏杨宝峰安然
Owner HARBIN MEDICAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap